Trademark: OSQAY 2432008
Word
OSQAY
ID
2432008
Trademark Type
WORD
Status
Registered: Registered/protected
Application Date
01 March 2024
Registration Date
01 March 2024
Renewal Date
01 March 2034
Owner(s)
Service
WRAYS PTY LTD
Goods and Services:
Class 5:
Pharmaceutical preparations and substances for the treatment of osteoporosis; pharmaceutical preparations and substances for the alleviation of osteoporosis-related symptoms; pharmaceutical preparations and substances for the treatment of cartilage disorders; pharmaceutical preparations and substances for the treatment of bone disorders; pharmaceutical preparations and substances for the treatment of bone loss; pharmaceutical preparations and substances for the alleviation of bone-loss related symptoms; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures; pharmaceutical preparations and substances for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures; pharmaceutical preparations and substances for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture; pharmaceutical preparations for the treatment of menopause; pharmaceutical preparations and substances for the alleviation of menopause-related symptoms; pharmaceutical preparations and substances for use in relation to women’s health; pharmaceutical preparations and substances for use in rheumatology; pharmaceutical preparations and substances for the treatment of arthritis; pharmaceutical preparations and substances for the treatment of rheumatoid arthritis; pharmaceutical preparations and substances for the treatment of juvenile idiopathic polyarthritis; pharmaceutical preparations and substances for the treatment of active systemic juvenile idiopathic arthritis; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for use in the treatment of respiratory conditions; pharmaceutical preparations and substances for use in the treatment of coronavirus disease; ; pharmaceutical preparations and substances for use in the treatment of cytokine release syndrome; all the above being for human use.
Pharmaceutical preparations and substances for the treatment of osteoporosis; pharmaceutical preparations and substances for the alleviation of osteoporosis-related symptoms; pharmaceutical preparations and substances for the treatment of cartilage disorders; pharmaceutical preparations and substances for the treatment of bone disorders; pharmaceutical preparations and substances for the treatment of bone loss; pharmaceutical preparations and substances for the alleviation of bone-loss related symptoms; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures; pharmaceutical preparations and substances for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures; pharmaceutical preparations and substances for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture; pharmaceutical preparations for the treatment of menopause; pharmaceutical preparations and substances for the alleviation of menopause-related symptoms; pharmaceutical preparations and substances for use in relation to women’s health; pharmaceutical preparations and substances for use in rheumatology; pharmaceutical preparations and substances for the treatment of arthritis; pharmaceutical preparations and substances for the treatment of rheumatoid arthritis; pharmaceutical preparations and substances for the treatment of juvenile idiopathic polyarthritis; pharmaceutical preparations and substances for the treatment of active systemic juvenile idiopathic arthritis; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for use in the treatment of respiratory conditions; pharmaceutical preparations and substances for use in the treatment of coronavirus disease; ; pharmaceutical preparations and substances for use in the treatment of cytokine release syndrome; all the above being for human use.